| 1 | lifesaving cell and gene | | | | | | | 4 | 0.48% |
| 2 | widespread patient access to | | | | | | | 4 | 0.48% |
| 3 | foster mba chief executive | | | | | | | 4 | 0.48% |
| 4 | c foster mba chief | | | | | | | 4 | 0.48% |
| 5 | jason c foster mba | | | | | | | 4 | 0.48% |
| 6 | advisor at ori biotech | | | | | | | 3 | 0.36% |
| 7 | to lifesaving cell and | | | | | | | 3 | 0.36% |
| 8 | access to lifesaving cell | | | | | | | 3 | 0.36% |
| 9 | patient access to lifesaving | | | | | | | 3 | 0.36% |
| 10 | enable widespread patient access | | | | | | | 3 | 0.36% |
| 11 | mba chief executive officer | | | | | | | 3 | 0.36% |
| 12 | veraitch phd founder and | | | | | | | 2 | 0.24% |
| 13 | officer jason c foster | | | | | | | 2 | 0.24% |
| 14 | chief executive officer and | | | | | | | 2 | 0.24% |
| 15 | prof chris mason md | | | | | | | 2 | 0.24% |
| 16 | phd frcs fmedsci cofounder | | | | | | | 2 | 0.24% |
| 17 | director ori biotech jason | | | | | | | 2 | 0.24% |
| 18 | cell and gene therapies | | | | | | | 2 | 0.24% |
| 19 | chris mason md phd | | | | | | | 2 | 0.24% |
| 20 | lee unroe vp marketing | | | | | | | 2 | 0.24% |
| 21 | phd founder and chief | | | | | | | 2 | 0.24% |
| 22 | biotech jason c foster | | | | | | | 2 | 0.24% |
| 23 | farlan veraitch phd founder | | | | | | | 2 | 0.24% |
| 24 | ori biotech jason c | | | | | | | 2 | 0.24% |
| 25 | phd manufacturing and strategic | | | | | | | 2 | 0.24% |
| 26 | md phd frcs fmedsci | | | | | | | 2 | 0.24% |
| 27 | clare chairman of the | | | | | | | 2 | 0.24% |
| 28 | prof bruce levine phd | | | | | | | 2 | 0.24% |
| 29 | unsubscribe at any time | | | | | | | 2 | 0.24% |
| 30 | hay phd investor director | | | | | | | 2 | 0.24% |
| 31 | jonathan hay phd investor | | | | | | | 2 | 0.24% |
| 32 | head of process development | | | | | | | 2 | 0.24% |
| 33 | mason md phd frcs | | | | | | | 2 | 0.24% |
| 34 | frcs fmedsci cofounder and | | | | | | | 1 | 0.12% |
| 35 | fmedsci cofounder and nonexecutive | | | | | | | 1 | 0.12% |
| 36 | director ori biotech prof | | | | | | | 1 | 0.12% |
| 37 | ori biotech prof chris | | | | | | | 1 | 0.12% |
| 38 | biotech prof chris mason | | | | | | | 1 | 0.12% |
| 39 | skip to content menu | | | | | | 1 | 0.12% |
| 40 | board prof chris mason | | | | | | | 1 | 0.12% |